We are pleased to announce the official registration of Mounjaro® in Jordan, marking an important advancement in expanding access to innovative treatment options for patients across the Kingdom.
This milestone reflects a strong collaboration between Eli Lilly and Company and Arab Drug Store Co. (Shocair Group), driven by a shared commitment to improving patient outcomes and addressing areas of high unmet medical need.
With its introduction to the Jordanian market, Mounjaro® represents a new step forward in delivering advanced therapies and supporting the evolution of healthcare in the Kingdom.
Leave a Reply